Enlivex ENLV 深 沪
等待开盘 10-06 09:30:00 美东时间
0.3655
-0.022
-5.63%
华盛通- 最 高1.66
- 今 开0.40
- 成交量 39.37万股
- 最 低 0.3607
- 昨 收 0.3873
- 总市值 6715.4777
- 52周最高 27.15
- 市盈率 静 --
- 换手率 2142.85%
- 52周最低 0.3607
- 委 比 66.67%
- 总股本 1.84万
- 历史最高 673.50
- 量 比 0.57
- 振 幅 335.48%
- 历史最低 0.3607
- 每 手 1
- 风险率 5.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enlivex shares are trading lower after the company announced a 1-for-15 reverse split.
Enlivex shares are trading lower after the company announced a 1-for-15 reverse...
07-07 20:03
Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B
Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026,
06-22 20:54
Dow Jumps 300 Points; Waldencast Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-11-25 01:08
D. Boral Capital Downgrades Enlivex Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Enlivex Therapeutics (NASDAQ:ENLV) from Buy to Hold.
2025-11-24 23:41
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
2025-11-24 22:47
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Enlivex Therapeutics will present data on its Allocetra™ therapy for knee osteoarthritis at the EULAR Congress in Barcelona. The presentation will highlight promising results from ongoing Phase I/II trials, including pain reduction and improved joint function, with Phase II data expected by August 2025.
2025-06-10 12:30
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $6 price target.
2024-09-09 18:22
EF Hutton Initiates Coverage On Enlivex Therapeutics with Buy Rating, Announces Price Target of $13
EF Hutton analyst Jason Kolbert initiates coverage on Enlivex Therapeutics (NASDAQ:ENLV) with a Buy rating and announces Price Target of $13.
2024-08-27 20:07
